RET and cancer: The discovery of driver oncogenes with aberrant tyrosine kinase activation, such as ALK, ROS1, RET, or NTRK1 gene rearrangement in cancers, continues to change the therapeutic strategies and treatment regimens accompanied with the development of targeted therapies.